{"id":"NCT00904995","sponsor":"M.D. Anderson Cancer Center","briefTitle":"Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis","officialTitle":"Kinetics of 1, 3 Beta-d- Glucan Assay in Patients With Hematologic Malignancies Receiving Voriconazole Prophylaxis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-05","primaryCompletion":"2010-07","completion":"2010-07","firstPosted":"2009-05-20","resultsPosted":"2011-05-12","lastUpdate":"2012-08-07"},"enrollment":23,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Leukemia","Fungal Infection"],"interventions":[{"type":"DRUG","name":"Voriconazole","otherNames":["Vfend"]},{"type":"DRUG","name":"Voriconazole","otherNames":["Vfend"]}],"arms":[{"label":"Group 1 - Oral","type":"EXPERIMENTAL"},{"label":"Group 2 - IV + Oral","type":"EXPERIMENTAL"}],"summary":"Objectives:\n\nTo investigate the relationship between the administration of intravenous (IV) and oral voriconazole (vori) and the occurrence of false positive (1,3) beta-d- glucan (BG) relative to the standard assessment criteria used to diagnose invasive fungal infection in patients with hematologic malignancies.","primaryOutcome":{"measure":"Percentage of Samples With BG Levels > 60pg/ml","timeFrame":"Up to 42 days","effectByArm":[{"arm":"Group 1 - Oral","deltaMin":4,"sd":null},{"arm":"Group 2 - IV + Oral","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://www.mdanderson.org"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":[]}}